Comparison of the efficacy of gefitinib in patients with non-small cell lung cancer according to the type of epidermal growth factor receptor mutation

S Igawa, M Kasajima, M Ishihara, M Kimura, Y Hiyoshi… - Oncology, 2014 - karger.com
Background: Exon 19 deletion and L858R point mutation of the epidermal growth factor
receptor (EGFR) are the most commonly encountered EGFR mutations in non-small cell …

EGFR exon 19 deletion is associated with favorable overall survival after first-line gefitinib therapy in advanced non–small cell lung cancer patients

YW Choi, SY Jeon, GS Jeong, HW Lee… - American journal of …, 2018 - journals.lww.com
Objectives: Exon 19 deletion and L858R mutation in exon 21 of the epidermal growth factor
receptor (EGFR) are both common mutations that predict a good response to EGFR tyrosine …

The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer …

JM Sun, YW Won, ST Kim, JH Kim, YL Choi… - Journal of cancer …, 2011 - Springer
Background Epidermal growth factor receptor (EGFR) mutations are associated with
sensitivity to gefitinib or erlotinib in non-small cell lung cancer (NSCLC). We investigated the …

First-or second-line therapy with gefitinib produces equal survival in non–small cell lung cancer

JY Wu, CJ Yu, CH Yang, SG Wu, YH Chiu… - American journal of …, 2008 - atsjournals.org
Rationale: Gefitinib is effective in treating patients with non–small cell lung cancer (NSCLC)
with epidermal growth factor receptor (EGFR) mutations. Deletions in exon 19 and L858R in …

[HTML][HTML] Effectiveness of gefitinib against non–small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q

S Watanabe, Y Minegishi, H Yoshizawa… - Journal of thoracic …, 2014 - Elsevier
Introduction: In non–small-cell lung cancer, an exon 19 deletion and an L858R point
mutation in the epidermal growth factor receptor (EGFR) are predictors of a response to …

Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations

K Sugio, H Uramoto, T Onitsuka, M Mizukami, Y Ichiki… - Lung Cancer, 2009 - Elsevier
BACKGROUND: This study prospectively assessed the efficacy of gefitinib and the survival
benefit for non-small cell lung cancer (NSCLC) patients with epidermal growth factor …

A phase II study of gefitinib as a first-line therapy for advanced non-small cell lung cancers with epidermal growth factor receptor (EGFR) gene mutations

H Asahina, K Yamazaki, I Kinoshita, S Ogura… - Journal of Clinical …, 2006 - ascopubs.org
13014 Background: Activating mutations in exon 18–21 of the epidermal growth factor
receptor (EGFR) gene have been reported to be a predictor of response to gefitinib. We …

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non–small cell lung cancer patients treated with gefitinib or …

DM Jackman, BY Yeap, LV Sequist, N Lindeman… - Clinical Cancer …, 2006 - AACR
Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) have been
detected in patients with non–small cell lung cancer (NSCLC) and are associated with …

Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response

JY Wu, SG Wu, CH Yang, CH Gow, YL Chang… - Clinical Cancer …, 2008 - AACR
Purpose: Clinical reports about responsiveness to gefitinib treatment in patients of non-small
cell lung cancer (NSCLC) with mutations in exon 20 of epidermal growth factor receptor …

Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous …

N Sunaga, Y Tomizawa, N Yanagitani, H Iijima, K Kaira… - Lung Cancer, 2007 - Elsevier
PURPOSE: Mutations in the epidermal growth factor receptor (EGFR) gene are associated
with increased sensitivity of non-small cell lung cancer (NSCLC) to gefitinib, an EGFR …